27th week of 2015 patent applcation highlights part 20 |
Patent application number | Title | Published |
20150183703 | SYNTHESIS OF DIACIDS - The invention relates to a process for preparing a dicarboxylic acid comprising the steps: (a) heating a lactone in the presence of a first catalyst system to produce an alkenoic acid; and (b) contacting the alkenoic acid with carbon monoxide, water and a second catalyst system to produce a reaction composition comprising the second catalyst system and the dicarboxylic acid. | 2015-07-02 |
20150183704 | PROCESS FOR THE PREPARATION OF AZELEIC ACID FROM 9-OCTADECENEDIOIC ACID - The invention relates to a process for the preparation of azelaic acid or alkyl azelate starting from mono-unsaturated 9-octadecenedioic acid or its corresponding alkylester characterized in that the process comprises at least the following step: reacting the mono-unsaturated 9-octadecene dioic acid or its corresponding alkylester with hydrogen peroxide in the presence of an organic carboxylic acid other than 9-octadecene dioic acid and a suitable catalyst to effect cleavage of the double bond in the mono-unsaturated 9-octadecene dioic acid or its corresponding alkylester. The invention further relates to the azelaic acid or alkyl azelate obtainable by the process according to the invention and to the use of azelaic acid or alkyl azelate or monomers derived there from for the preparation of a polymer, especially a polyamide. | 2015-07-02 |
20150183705 | Oxidation Process For Preparing Purified Aromatic Carboxylic Acids - A process including: (a) contacting an aqueous solution including a crude aromatic carboxylic acid with an oxygen source in the presence of an oxidation catalyst including at least one of Ru, Au, Pt, Ir or V, and oxides, alloys, salts and mixtures thereof; and (b) purifying the product of step (a) to form a purified aromatic carboxylic acid. | 2015-07-02 |
20150183706 | PROCESSES FOR MAKING CYCLOHEXANE COMPOUNDS - This invention relates to hydrogenation processes for making cyclohexane compounds. More specifically, this invention relates to hydrogenation processes in the presence of tertiary amide solvent compounds, as well as compositions that can result from such processes. The invention thus provides processes for making cyclohexanecarboxylic acid compounds and processes for making hydroxymethylcyclohexane compounds. | 2015-07-02 |
20150183707 | OZONOLYSIS OPERATIONS FOR GENERATION OF REDUCED AND/OR OXIDIZED PRODUCT STREAMS - The present invention relates to methods for safe and efficient use of hydrogen and oxygen in ozonolysis operations. The invention also relates to an ozonolysis process involving elements of both reductive and oxidative ozonolysis which are integrated in a continuous process. In one embodiment, the ozonolysis process of the present invention uses hydrogen and/or oxygen generated from water and electricity, which may be recycled to generate water and/or electricity. | 2015-07-02 |
20150183708 | Renewable Acrylic Acid Production and Products Made Therefrom - Processes and methods for making biobased acrylic acid products including acrylic acid, acrylic acid oligomers, acrylic acid esters, acrylic acid polymers and articles from renewable carbon resources are described herein. | 2015-07-02 |
20150183709 | Pressurized Crude Aromatic Carboxylic Acid Feed Mixes - Processes for manufacturing a purified aromatic carboxylic acid include heating a purification reaction mixture in a pre-heating zone, the purification reaction mixture comprising a crude aromatic carboxylic acid and a solvent, and purifying the crude aromatic carboxylic acid in the purification reaction mixture to form a purified aromatic carboxylic acid product. One or more operations are maintained at a pressure above ambient in order to achieve energy savings. | 2015-07-02 |
20150183710 | High-Pressure Condensate Recycle in the Manufacture of Purified Aromatic Carboxylic Acids - Processes for manufacturing purified aromatic carboxylic acids include: generating high-pressure steam from boiler feed water supplied to a boiler; heating a crude aromatic carboxylic acid using the high-pressure steam, whereby the high pressure steam is condensed to form a high-pressure condensate; and purifying the crude aromatic carboxylic acid to form a purified aromatic carboxylic acid. The boiler feed water includes at least a portion of the high-pressure condensate and makeup boiler feed water from at least one additional source. | 2015-07-02 |
20150183711 | METHODS AND APPARATUS FOR ISOLATING DICARBOXYLIC ACID - Disclosed is a method for purifying aromatic dicarboxylic acid such as isophthalic acid or terephthalic acid. The process treats a crude carboxylic acid (CCA) composition by:
| 2015-07-02 |
20150183712 | METHODS AND APPARATUS FOR ISOLATING DICARBOXYLIC ACID - Disclosed is a method for purifying aromatic dicarboxylic acid such as isophthalic acid or terephthalic acid. The process treats a crude carboxylic acid (CCA) composition by:
| 2015-07-02 |
20150183713 | Process For Using Dehydration Tower Condensate As A Purification Makeup Solvent - Processes for manufacturing purified aromatic carboxylic acids include: oxidizing a substituted aromatic compound in a reaction zone to form a crude aromatic carboxylic add; transferring a vapor phase from the reaction zone to a separation zone, the vapor phase containing water and a plurality of organic compounds including at least one oxidation by-product; withdrawing an organic-depleted water stream from the separation zone and combining at least a portion of the organic-depleted water stream with at least a portion of the crude aromatic carboxylic acid in a purification zone; and purifying the crude aromatic carboxylic acid in the purification zone. | 2015-07-02 |
20150183714 | METHYLIDENE MALONATE PROCESS - An improvement in the production of methylidene malonates is attained by use of specific reaction phase and/or separation phase polymerization inhibitors and combinations thereof. | 2015-07-02 |
20150183715 | ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, having the structure: | 2015-07-02 |
20150183717 | PROCESS FOR IMPROVED RECOVERY OF ONIUM HYDROXIDE FROM COMPOSITIONS CONTAINING PROCESS RESIDUES - A process for recovering an onium hydroxide from a composition containing onium ions and a process residue, including providing a composition containing onium ions and a process residue; adding a quantity of a surfactant to the composition to obtain a surfactant-modified composition; providing a cation exchange media; collecting the onium ions by applying the surfactant-modified composition to the cation exchange media wherein the onium ions become bound to and retained by the cation exchange media and the process residue and the surfactant do not become bound to the cation exchange media and are substantially not retained by the cation exchange media; and recovering the onium ions from the cation exchange media as an onium hydroxide by applying a cation-containing hydroxide composition to the cation exchange media. | 2015-07-02 |
20150183718 | METHOD FOR PRODUCING 2-(ISOPROPYLAMINO)ETHANOL - The present invention relates to a method of producing 2-(isopropylamino)ethanol, including subjecting acetone, 2-aminoethanol, and hydrogen to a vapor-phase catalytic reaction in the presence of a noble metal-containing catalyst. According to the present invention, 2-(isopropylamino)ethanol can be industrially obtained in a large amount and with high efficiency through the vapor-phase catalytic reaction of acetone, 2-aminoethanol, and hydrogen. 2-(Isopropylamino)ethanol is a compound useful as a raw material for a drug, an agricultural chemical, or the like. | 2015-07-02 |
20150183719 | PROCESS FOR MAKING ETHANOLAMINES - A process for the preparation of ethanolamines comprising reacting a water-ammonia solution with ethylene oxide to form an effluent reaction mixture comprising unreacted ammonia, water and ethanolamines. This effluent reaction mixture is then subjected to a succession of steps to, inter alia, separate the ethanolamines. | 2015-07-02 |
20150183720 | PROCESS FOR MAKING ETHANOLAMINES - A process for the preparation of ethanolamines comprising reacting a water-ammonia solution comprising ammonia and water with ethylene oxide. | 2015-07-02 |
20150183721 | AMINO-ALCOHOL ANALOGUES AND USES THEREOF - This invention relates to amino-alcohol analogues and uses thereof in the treatment of diseases and disorders such as cancer, neurodegenerative and metabolic diseases and genetic storage diseases. | 2015-07-02 |
20150183722 | Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein - The present invention relates to a compound of formula A, wherein R is alkyl. | 2015-07-02 |
20150183723 | Calcilytic Compounds - Novel calcilytic compounds and methods of using them are provided. | 2015-07-02 |
20150183724 | PROCESS FOR PRODUCING AMINE COMPOUNDS - The present invention provides processes for producing amine compounds. The amine compounds include diammonium compounds and amino acid derivatives. | 2015-07-02 |
20150183725 | METHOD OF PRODUCING BASIC AMINO ACID OR BASIC AMINO ACID SALT - [Problem] It is to provide a method of producing basic amino acid or basic amino acid salt suitable for each use for medicine, industrial use, feed, food additive and the like, by a simple method to remove HCl from HCl salt of basic amino acid efficiently. | 2015-07-02 |
20150183726 | CRYSTALLINE SALTS OF (Z)-O-OCTADEC-9-EN-1-YL O,O-DIHYDROGEN PHOSPHOROTHIOATE - Here provided are a salt of Z)—O-octadec-9-en-1-yl O,O-dihydrogen phosphorothioate with an L-lysine addition in crystalline form and methods of making and using the same. | 2015-07-02 |
20150183727 | METHOD FOR THE PREPARATION OF 1-ARYL-1-ALKYL-2-ALKYL-3-DIALKYLAMINOPROPANE COMPOUNDS - The present invention refers to the preparation of 1-aryl-1-alkyl-2-alkyl-3-dialkylamino-propane compounds, such as tapentadol, using a diastereoselective Eschenmoser-Claisen or Ireland-Claisen rearrangement. | 2015-07-02 |
20150183728 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES - The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance. | 2015-07-02 |
20150183729 | PROCESS FOR THE PREPARATION OF ISOBUTYLIDENE DIUREA - The invention relates to a process comprising: reacting isobutyraldehyde with an aqueous solution of urea in the presence of a phase transfer catalyst to form isobutylidene diurea. Preferably, the phase transfer catalyst is a quaternary ammonium salt, more preferably benzyltriethylammonium chloride. Even more preferably, the process is performed in one pot. | 2015-07-02 |
20150183730 | PACTAMYCIN ANALOGS AND METHODS OF MAKING THEREOF - This disclosure describes the molecular cloning of a pactamycin biosynthetic gene cluster from | 2015-07-02 |
20150183731 | Cyclic process for the production of taurine from monoethanolamine - A method is disclosed for the production of taurine in high yield by a cyclic process of reacting monoethanolamine, sulfuric acid, and ammonium sulfite in the presence of additives to inhibit the hydrolysis of 2-aminoethyl hydrogen sulfate intermediate. The cyclic process is economical and little waste is generated. | 2015-07-02 |
20150183732 | Processes For The Preparation Of 2,5-Dihydroxybenzenesulfonic Acid Salts - Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts of formula (I) and a crystalline form of potassium 2,5 2,5-dihydroxybenzenesulfonic acid are provided. | 2015-07-02 |
20150183733 | Process for Depolymerizing Polysulfides and the Preparation of Bis-Mercapto-Diethers - The invention related to a process for the preparation of a bismercaptodiether by reacting a polysulfide with a monothiol in the presence of a base and to a process for the depolymerization of a polysulfide by reacting said polysulfide with a monothiol in the presence of a base. | 2015-07-02 |
20150183734 | TRANSESTERIFICATION PROCESS OF RETINOL ESTERS - The present invention relates to a transesterification process of specific compounds comprising isoprenoid units. | 2015-07-02 |
20150183735 | PYRROLIDINYL DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS - The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
| 2015-07-02 |
20150183736 | CYANINE-CONTAINING COMPOUNDS FOR CANCER IMAGING AND TREATMENT - This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields. | 2015-07-02 |
20150183737 | COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION - Methods for selectively inhibiting endocannabinoid oxygenation but not arachidonic acid oxygenation. In some embodiments, the methods include contacting a COX-2 polypeptide with an effective amount of a substrate-selective COX-2 inhibitor. Also provided are methods for elevating a local endogenous cannabinoid concentrations; methods of reducing depletion of an endogenous cannabinoid; methods for inducing analgesia; methods of providing anxiolytic therapy; methods for providing anti-depressant therapy; and compositions for performing the disclosed methods. | 2015-07-02 |
20150183738 | 3-N-BUTYL-1-ISOINDOLINONE AND USE THEREOF FOR PREVENTING OR TREATING CEREBRAL INFARCTION - 3-n-Butyl-1-isoindolinone and use thereof for preventing or treating cerebral infarction. The compound is prepared by: 1) employing phthalimide as a starting reactant, contacting a nucleophilic Grignard reagent with the original reactant to add an alkyl group to a carbonyl carbon of an amide bond of the original reactant, thus yielding an intermediate; and 2) removing an oxygen atom connected to a third carbon atom of the intermediate in the presence of boron trifluoride diethyl etherate as a catalyst and triethylsilane as a reductant. | 2015-07-02 |
20150183739 | PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF - Processes for the preparation of certain isoindole compounds, and isotopologues thereof, are provided. In some embodiments, the processes comprise catalytic assymetrical hydrogenation with hydrogen gas or deuterium gas in a solvent containing exchangeable proton or deuterium for proton-deuterium exchange. | 2015-07-02 |
20150183740 | Method For Preparation of Octahydrocyclopenta[c]pyrrole - The invention discloses a method for the preparation of octahydrocyclopenta[c]pyrrole, also called 3-azabicyclo[3.3.0]octane, by hydrogenation of 1,2-dicyanocyclo-1-pentene. | 2015-07-02 |
20150183741 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS - Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). | 2015-07-02 |
20150183742 | PROCESS FOR THE PREPARATION OF ATAZANAVIR BISULFATE - The present invention relates to an improved process for the preparation of Atazanavir bisulfate Form A. The present invention also relates to a pharmaceutical composition using the Atazanavir bisulfate Form A of the invention. | 2015-07-02 |
20150183743 | COMPOUND AND USE OF COMPOUND TO PREPARE A RADIOLABELLED COMPOUND - The invention is directed to a compound according to formula (1) wherein R | 2015-07-02 |
20150183744 | ACTIVATORS OF HUMAN PYRUVATE KINASE - Disclosed are pyruvate kinase M2 activators which are compounds of Formula (I), including those of Formula (II), wherein A | 2015-07-02 |
20150183745 | TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF - The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F | 2015-07-02 |
20150183746 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES - Disclosure is provided for imidazole-phenyl derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same. | 2015-07-02 |
20150183747 | Pharmaceutical Compositions - The present invention is directed to pharmaceutical compositions comprising: (a) a cyclopolysaccharide and (b) a compound of Formula (I) or its pharmaceutical acceptable salt: | 2015-07-02 |
20150183748 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS - The present invention provides compostions and methods useful for treating and preventing neurodenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders with abnormal blood brain barrier (BBB) function, for example neurodegenerative diseases with a permeable BBB, such as but not limited to, Alzhiemer's Disease, Huntington's Disease, Parkinson's Disease and Vascular Dementia. | 2015-07-02 |
20150183749 | 5-FLUORO-4-IMINO-3-(ALKYL/SUBSTITUTED ALKYL)-1-(ARYLSULFONYL)-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE AND PROCESSES FOR THEIR PREPARATION - Provided herein are 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1H)-one and processes for their preparation which may include the use of an alkali carbonate and an alkylating agent | 2015-07-02 |
20150183750 | 5-FLUORO-4-IMINO-3-(ALKYL/SUBSTITUTED ALKYL)-1-(ARYLSULFONYL)-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE AND PROCESSES FOR THEIR PREPARATION - Provided herein are 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1H)-one and processes for their preparation which may include the use of an alkali alkoxide and an alkylating agent | 2015-07-02 |
20150183751 | PROCESS FOR RILPIVIRINE USING NOVEL INTERMEDIATE - The present invention provides a commercially viable process for preparing rilpivirine and its pharmaceutically acceptable acid addition salts thereof in high yields using novel intermediate. | 2015-07-02 |
20150183752 | CRYSTALLINE COMPOUNDS - Provided herein are various polymorph forms of N-(3-{[(2Z)-3-[(2-chloro-5-methoxyphenyl)amino]quinoxalin-2(1H)-ylidene]sulfamoyl}phenyl)-2-methylalaninamide. | 2015-07-02 |
20150183753 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES - This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia. | 2015-07-02 |
20150183754 | FATTY ACID INHIBITORS - Fatty acid inhibitors, pharmaceutical compositions including fatty acid inhibitors, methods for using fatty acid inhibitors to treat a variety of diseases, and methods for preparing fatty acid inhibitors are provided herein. | 2015-07-02 |
20150183755 | SPRAY OXIDATION PROCESS FOR PRODUCING 2,5-FURANDICARBOXYLIC ACID FROM HYDROXYMETHYLFURFURAL - A process is provided for carrying out an oxidation on a sprayable feed including a furanic substrate to be oxidized and a catalytically effective combination of cobalt, manganese, and bromide components for catalyzing the oxidation of the furanic substrate, which process comprises spraying the feed into a reactor vessel as a mist, supplying an oxidant, reacting the furanic substrate and the oxidant, and managing the exothermic temperature rise due to the reaction through a selection and control of the operating pressure within the reactor vessel. A crude dehydration product from the dehydration of fructose, glucose or both, including 5-hydroxymethylfurfural, can be directly oxidized by the process to produce 2,5-furandicarboxylic acid in surprisingly increased yields. | 2015-07-02 |
20150183756 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS - The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof. | 2015-07-02 |
20150183757 | METHOD OF PRODUCING BERAPROST - An improved method is described for making single isomers of synthetic benzoprostacyclin analogue compounds, in particular the pharmacologically active 314-d isomer of beraprost. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds. | 2015-07-02 |
20150183758 | Process-Scale Synthesis of Urolithins - Disclosed is a method of preparing a urolithin, or an intermediate or analog thereof, having a dibenzo[b,d]pyran-6-one core. The method is especially advantageous for the large-scale preparation of urolithins or intermediates or analogs thereof. The method may optionally include the preparation of a urolithin, or an intermediate or analog thereof, as a pharmaceutically acceptable salt. | 2015-07-02 |
20150183759 | MACROCYCLIC PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY - The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides. | 2015-07-02 |
20150183760 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS - Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 2015-07-02 |
20150183761 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS - The invention relates to benzimidazole-carboxamide 5-HT | 2015-07-02 |
20150183762 | PROCESS FOR THE PREPARATION OF NILOTINIB - The present invention relates a process for the preparation of a compound of formula (I): | 2015-07-02 |
20150183763 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF - The present invention provides a pyrazole compound of the following general Formula [Ib] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use: | 2015-07-02 |
20150183764 | PROCESS FOR THE MANUFACTURE OF (E)-4-N,N-DIALKYLAMINO CROTONIC ACID IN HX SALT FORM AND USE THEREOF FOR SYNTHESIS OF EGFR TYROSINE KINASE INHIBITORS - The present invention is directed to an efficient process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form of formula I | 2015-07-02 |
20150183765 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof - Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. | 2015-07-02 |
20150183766 | CRYSTAL HAVING CRYSTAL HABITS AND PHARMACEUTICAL COMPOSITION OBTAINED BY PROCESSING THE CRYSTAL - An object is to provide means for improving the solubility of luliconazole. Disclosed is a crystal of luliconazole wherein the crystal has such a crystal habit that (021) plane is a specific crystal growth plane. | 2015-07-02 |
20150183767 | NOVEL POLYMORPHS OF AZILSARTAN MEDOXOMIL - The present invention provides a novel amorphous Form of azilsartan acid, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides novel crystalline Forms of azilsartan medoxomil, processes for their preparations and pharmaceutical compositions comprising them. The present invention further provides a novel amorphous Form of azilsartan medoxomil potassium, process for its preparation and pharmaceutical compositions comprising it. The present invention further provides a novel process for the preparation of azilsartan medoxomil potassium crystalline Form II. | 2015-07-02 |
20150183768 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE - A heteroaromatic methyl cyclic amine derivative represented by formula (IA) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of an orexin (OX) receptor antagonist activity. | 2015-07-02 |
20150183769 | Azetidine Derivatives - Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: | 2015-07-02 |
20150183770 | 5-RING HETEROAROMATIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS - The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for the treatment and/or prevention of diseases, and medicaments containing same. | 2015-07-02 |
20150183771 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound. | 2015-07-02 |
20150183772 | ALKYLATION OF AZOLES - In one aspect, methods for the alkylation of azoles are described herein. In some embodiments, a method for the C2 alkylation of an azole compound comprises providing an azolium salt comprising an N-allyl substituent, reacting the N-allyl azolium salt with an aldehyde to provide a reaction product mixture comprising a ketone and N-allyl-N,X-ketene acetal, and providing the C2-alkylated azole compound by Claisen rearrangement of the N-allyl-N,X-ketene acetal, wherein X is selected from the group consisting of S, N and O. | 2015-07-02 |
20150183773 | Substituted piperidines - The invention relates to novel substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders and tumour disorders. | 2015-07-02 |
20150183774 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors - The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same. | 2015-07-02 |
20150183775 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2015-07-02 |
20150183776 | DI- AND TRI-HETEROARYL DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION - The present invention relates to certain di- and tri-heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, and multiple system atrophy. | 2015-07-02 |
20150183777 | ANTI-MUCUS DRUGS AND USES THEREFOR - Disclosed are methods of identifying, generating and synthesizing compounds that inhibit MAPK13 activity. In various embodiments, compounds, salts thereof and prodrugs thereof of the present teachings can be useful for the treatment of diseases and disorders that involve excess mucus production. | 2015-07-02 |
20150183778 | New non-annulated thiophenylamides - The invention provides novel compounds having the general formula (I) | 2015-07-02 |
20150183779 | SOLID STATE FORM OF VEMURAFENIB CHOLINE SALT - The present invention relates to Vemurafenib choline salt, solid state forms thereof, processes for preparation thereof and formulations thereof. The present invention also relates to the use of the solid state forms of Vemurafenib choline salt for preparing Vemurafenib or other Vemurafenib salts, and solid state forms thereof. Vemurafenib has the following chemical structure: | 2015-07-02 |
20150183780 | USE OF VEGFR-3 INHIBITORS FOR TREATING HEPATOCELLULAR CARCINOMA - This invention is related to the use of inhibitors of vascular endothelial growth factor receptor 3 for treating hepatocellular carcinoma. | 2015-07-02 |
20150183781 | 5-(1H-Pyrazol-4-yl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors - The present application relates to novel 5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. | 2015-07-02 |
20150183782 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV - The invention relates to a compound of Formulae I and/or II: | 2015-07-02 |
20150183783 | PROCESSES FOR THE PREPARATION OF AN APOPTOSIS-INDUCING AGENT - Provided herein is a process for the preparation of an apoptosis-inducing agent, and chemical intermediates thereof. Also provided herein are novel chemical intermediates related to the process provided herein. | 2015-07-02 |
20150183784 | BROMODOMAIN INHIBITORS - The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease. | 2015-07-02 |
20150183785 | ANTIPARISITIC DIHYDROAZOLE COMPOUNDS AND COMPOSITIONS COMPRISING SAME - The present invention relates to novel dihydroazole of formula (I) and salts thereof: | 2015-07-02 |
20150183786 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS - The present invention relates to compounds of formula (I) having a bicyclic aza-amides scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said bicyclic aza-amides compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions. | 2015-07-02 |
20150183787 | PROPELLANE-BASED COMPOUNDS AND THE USE THEREOF - The application is directed to compounds of Formula I | 2015-07-02 |
20150183788 | XANTHINE DERIVATIVE - The present invention discloses a xanthine derivative having the structure of the following general formula (I) or a pharmaceutically acceptable salt thereof; further discloses a preparation method for the xanthine derivative or a pharmaceutically acceptable salt thereof; and further discloses the use of the xanthine derivative or a pharmaceutically acceptable salt thereof. Through experiments of DPP-IV activity inhibition experiments in vitro, impact on glucose tolerance in normal mice and impact on blood glucose in spontaneous diabetic mice, it proves that the compounds and pharmaceutically acceptable salts thereof show good DPP-IV inhibition activity, can be applied to prepare medicines for treating dipeptidyl peptidase IV-related diseases, and more particularly, can be applied to the use of medicines for treating type II diabetes or diseases of abnormal glucose tolerance. | 2015-07-02 |
20150183789 | IMPROVED PROCESS FOR THE PREPARATION OF PRALATREXATE - An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in high yield. | 2015-07-02 |
20150183790 | FUSED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS - The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases. | 2015-07-02 |
20150183791 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE - Imidazo[1,2-b]pyridazine-based compounds of the formula: | 2015-07-02 |
20150183792 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE - Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: | 2015-07-02 |
20150183793 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR - Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of Fms, Kit, Flt3, TrkA, TrkB and TrkC kinase protein. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of one or more of Fms, Kit, Flt3, TrkA, TrkB and TrkC, including rheumatoid arthiritis, osteoarthritis, osteoporosis, peri-prosthetic osteolysis, systemic sclerosis, demyelinating disorders, multiple sclerosis, Charcot Marie Tooth syndrome, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, global ischemia, ulcerative colitis, Crohn's disease, immune thrombocytopenic purpura, atherosclerosis, systemic lupus erythematosis, myelopreparation for autologous transplantation, transplant rejection, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, renal hypertrophy, type I diabetes, acute pain, inflammatory pain, neuropathic pain, acute myeloid leukemia, melanoma, multiple myeloma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, ovarian cancer, gliomas, glioblastoma, neurofibromatosis, osteolytic bone metastases, brain metasteses, gastrointestinal stromal tumors, and giant cell tumors. | 2015-07-02 |
20150183794 | AZA-BICYLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS - The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, | 2015-07-02 |
20150183795 | CRYSTALLINE FORMS OF 1-(5'-(5-(3,5-DICHLORO-4-FLUOROPHENYL)-5-(TRIFLUORO-METHYL)-4,5-DIHYDROIS- OXAZOL-3-YL)-3'H-SPIRO[AZETIDINE-3,1'-ISOBENZOFURAN]-1-YL)-2-(METHYLSULFON- YL)ETHANONE - The present invention relates to novel crystalline modifications of 1-(5′-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoro-methyl)-4,5-dihydroisoxazol-3-yl)-3′H-spiro[azetidine-3,1′-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone. The present invention also describes compositions and methods of treating a parasitic infection or infestation in an animal in need thereof. The present invention also relates to processes for making the crystalline forms. | 2015-07-02 |
20150183796 | METHOD OF SYNTHESIS OF A COMPOSITION CONTAINING AT LEAST ONE INTERNAL DEHYDRATION PRODUCT OF A HYDROGENATED SUGAR BY HETEROGENEOUS CATALYSIS - A simple, low cost, environmentally friendly and sustainable process for the production of internal dehydration products of hydrogenated sugar, implementing trivalent metal phosphate (metal (III) phosphates) as catalysts during the dehydratation step. | 2015-07-02 |
20150183797 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT - The present invention relates to a compound inhibiting Hsp90 and a pharmaceutical composition comprising the same as an active ingredient. The compounds represented by formula 1 and formula 2 of the present invention suppress the expression of Hsp90 so that they can inhibit the accumulation of HIF-1α, the Hsp90 client protein, and also efficiently inhibit the activation of VEGF. In addition, these compounds display low cytotoxicity, so that they can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent. | 2015-07-02 |
20150183798 | MONOMERIC TRIOXANE AMIDE SULFUR COMPOUNDS - Anilide derivatives of the natural trioxane artemisinin were prepared and evaluated for antimalarial efficacy in | 2015-07-02 |
20150183799 | Tricyclic Compounds and PBK Inhibitors Containing the Same - Tricyclic compounds are provided. These compounds are PBK inhibitors, and are useful for the treatment of PBK related diseases, including cancer. | 2015-07-02 |
20150183800 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO - GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: | 2015-07-02 |
20150183801 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 - The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. | 2015-07-02 |
20150183802 | TRICYCLIC SULFONAMIDE DERIVATIVES - The invention relates to derivatives of formula (I), | 2015-07-02 |
20150183803 | (3S,11aR)-6-[(PHENYLMETHYL)OXY]-3-METHYL-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-- a]PYRIDO[1,2-d]PYRAZINE-5,7-DIONE OF THE FORMULA P-9 AND/OR (3S,11aR)-6-[(PHENYLMETHYL)OXY]-8-BROMO-3-METHYL-2,3,11,11a-TETRAHYDROOXA- ZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-DIONE OF THE FORMULA P-10 - The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC. | 2015-07-02 |